ACOX1 and metabolic dysfunction-associated steatotic liver disease: Our research showed that miR-103-3p may inhibit ALT and AST to improve inflammation, decrease ROS and H2O2 levels to improve oxidative stress, and increase ATP levels to alleviate NAFLD damage by targeting ACOX1.